17th Jun 2025 09:00
Dr. Martens plc (the "Company")
2025 Annual Report and Notice of Annual General Meeting
Further to the announcement of its preliminary results for the financial period ended 30 March 2025 and in accordance with UK Listing Rules 6.4.1R, 6.4.3R and 10.6.13R, the Company announces that the following documents have been submitted in unedited full text to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:
· Annual Report and Accounts for the financial period ended 30 March 2025 (the "2025 Annual Report")
· Notice of the 2025 Annual General Meeting (the "2025 Notice of Meeting"), which will take place at 9.30am on Thursday 10 July 2025 at 1-11 Hawley Crescent, Camden, London, NW1 8NP
· Proxy form for the 2025 Annual General Meeting
· Rules of the Dr. Martens Long Term Incentive Plan
In compliance with rule 6.3.5R of the Disclosure Guidance and Transparency Rules, the 2025 Annual Report and 2025 Notice of Meeting are also available in unedited full text on the Company's website, www.drmartensplc.com.
For further information, please contact:Paul Rolling, Head of Secretariat+447584243562
Bethany Barnes, Director of Investor Relations+447825187465
ENDS
About Dr. Martens
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/
Related Shares:
Dr. Martens